Search the Newsreel

Renaissance Technologies LLC Raises Position in Editas Medicine, Inc. $EDIT

Renaissance Technologies LLC increased its stake in Editas Medicine, Inc. by 30.7% in the first quarter of 2026, acquiring an additional 932,382 shares to own a total of 3.97 million shares valued at $9.8 million. Other institutional investors also adjusted their holdings, with hedge …

Price to book forward of Cingulate Inc. – NASDAQ:CINGW

This article provides the "Price to book forward" financial metric for Cingulate Inc. (NASDAQ: CINGW). It is presented as a snapshot from TradingView, indicating the period, value, and change percentage for this financial data point.

Cintas Corporation (NASDAQ:CTAS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Fifteen research firms have given Cintas Corporation (NASDAQ:CTAS) an average rating of "Moderate Buy," with an average 12-month target price of $212.31. The company recently reported strong quarterly earnings, beating analyst estimates, and announced an increased quarterly dividend. Several analysts have updated their ratings …

Billionaire Stanley Druckenmiller Bought This Biotech Stock That Has Surged 400%. Is It Still a Buy?

Key Points Druckenmiller initiated a new stake in Revolution Medicines in Q1. The biotech stock has skyrocketed on excitement about its lead cancer candidate, daraxonrasib. Revolution Medicine's valuation makes the stock a riskier proposition now.10 stocks we like better than Revolution Medicines › Stanley …

Prime Medicine, Inc. (NASDAQ:PRME) Given Average Recommendation of "Moderate Buy" by Brokerages

Prime Medicine, Inc. (NASDAQ:PRME) has received an average "Moderate Buy" recommendation from eight brokerages, with six analysts rating it a buy, one a strong buy, and one a sell. The average 12-month price target is $7.53, significantly higher than its recent share price of …

Berenberg conferma buy su Cucinelli; target sale a EUR97

Salt Funds Group Takes 5.45% Stake in Precinct Properties

Cineline India promoters acquire 21.36 lakh shares via warrant conversion

Carlton Investments (ASX:CIN): What Does the Discount to NTA Mean for Investors?

Star Sports Medicine unveils 2026 share incentive scheme to align talent and investors

China Cinda warns of sharp drop in H1 2026 profit despite stable operations

5 Insightful Analyst Questions From Cincinnati Financial’s Q2 Earnings Call

Cincinnati Financial's Q2 earnings call revealed the company missed Wall Street's revenue and non-GAAP profit expectations, attributed to modestly elevated catastrophe losses and persistent pricing discipline. Analysts questioned management on various topics including large commercial lines losses, commission structures, premium growth drivers, personal lines …

Cincinnati Financial Corporation Revenue Breakdown – DUS:CCJ

Cincinnati Financial Corporation (DUS:CCJ) generated €8.50 billion in revenue last year, with its Commercial Lines Insurance segment being the top performer at €4.14 billion. The United States contributed the most to the company's revenue, accounting for €10.75 billion. This report provides a breakdown of …

Cinemark (CNK) Stock Looks Cheap On Its 140% Five Year Run

Cinemark Holdings (CNK) has seen a 140.1% return over the past five years, presenting a mixed valuation picture. While a Discounted Cash Flow (DCF) model suggests the stock is undervalued by 34.3% due to strong cash flow generation, its P/E ratio of 24.8x is …

Is Revolution Medicines (RVMD) Fully Valued Following Its FDA Filing Win?

Revolution Medicines (RVMD) has seen significant stock price appreciation following the FDA's acceptance of its New Drug Application for daraxonrasib. Despite a 137.32% year-to-date increase, Simply Wall St's analysis suggests RVMD is 8.2% undervalued, with a fair value pegged at $204.38 based on its …

Why Billionaire Stanley Druckenmiller and Wall Street Analysts Love This Biotech Stock

Key Points Druckenmiller bought 316,000 shares of Revolution Medicines in the first quarter. The company doesn't generate revenue yet and lost $453 million in the first quarter. Revolution uses RAS proteins to treat aggressive cancers.10 stocks we like better than Revolution Medicines › Shares …

How Investors Are Reacting To Disc Medicine (IRON) Balancing Larger Losses With APOLLO Phase 3 FDA Alignment

Disc Medicine (IRON) reported a widening net loss in Q2 2026 but investors are focusing on clinical and regulatory milestones, particularly the FDA alignment for its bitopertin APOLLO Phase 3 trial. The company's investment narrative centers on its iron homeostasis platform converting late-stage clinical …

Lipocine Appoints Industry Veteran Grissinger to Board

Lipocine Inc. has appointed Michael J. Grissinger, an industry veteran with over two decades of senior leadership experience at Johnson & Johnson, to its Board of Directors. Grissinger's expertise in pharmaceutical licensing, corporate development, and M&A is expected to help advance Lipocine's clinical pipeline …

Edgestream Partners L.P. Invests $3.38 Million in nCino Inc. $NCNO

Edgestream Partners L.P. has made a new investment in nCino Inc. (NASDAQ:NCNO), acquiring 225,462 shares valued at approximately $3.38 million. Institutional investors and hedge funds collectively own 94.76% of nCino, with other firms also adjusting their stakes. Despite recent insider sales by the CEO …

Empowered Funds LLC Purchases 9,083 Shares of Cintas Corporation $CTAS

Empowered Funds LLC increased its stake in Cintas Corporation (NASDAQ:CTAS) by 31.9% in the first quarter, purchasing an additional 9,083 shares to bring its total holdings to 37,587 shares valued at approximately $6.36 million. Cintas reported strong quarterly earnings of $1.29 per share and …

Arrowstreet Capital Limited Partnership Purchases 571,413 Shares of nCino Inc. $NCNO

Arrowstreet Capital Limited Partnership significantly increased its stake in nCino Inc. (NASDAQ:NCNO) by purchasing 571,413 shares in the first quarter, bringing its total holdings to 613,770 shares valued at $9.2 million. Institutional investors now own 94.76% of nCino's stock, while analysts maintain a "Moderate …

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Recommendation of "Moderate Buy" by Analysts

TD Cowen Maintains Disc Medicine(IRON.US) With Buy Rating

TD Cowen has reiterated its Buy rating on Disc Medicine (IRON.US). The article does not provide specific details on the rationale behind this rating or any new price target.

Price to earnings forward of Revolution Medicines, Inc. – BOATS:RVMDW

The article focuses on the "Price to earnings forward" for Revolution Medicines, Inc. (RVMDW), listed on the Blue Ocean Alternative Trade System (BOATS). It presents financial information related to RVMDW, including market status and data provided by ICE Data Services and FactSet. The page …

Kentucky Retirement Systems Sells 13,271 Shares of Cintas Corporation $CTAS

Kentucky Retirement Systems significantly reduced its stake in Cintas Corporation (NASDAQ:CTAS) by 61.5% in the first quarter, selling 13,271 shares and retaining 8,315 shares valued at $1.4 million. Despite this, Cintas continues to perform strongly, exceeding quarterly earnings expectations with $1.29 EPS and $2.91 …

Montchanin Asset Management LLC Makes New Investment in Cintas Corporation $CTAS

Montchanin Asset Management LLC has invested approximately $3.23 million in Cintas Corporation, acquiring 19,093 shares, making it their ninth-largest holding. Cintas has consistently surpassed quarterly earnings expectations and recently increased its quarterly dividend to $0.52 per share. Analysts generally rate Cintas as a "Moderate …

Prime Medicine(PRME) Stock Options Chain | Quotes & News

This article provides access to the stock options chain for Prime Medicine (PRME), including detailed quotes and relevant news. It serves as a resource for investors interested in the company's options trading data and market developments.

Argent Capital Management LLC Buys 14,231 Shares of Cintas Corporation $CTAS

Argent Capital Management LLC significantly increased its stake in Cintas Corporation (NASDAQ:CTAS) by 64.2% in the first quarter, purchasing an additional 14,231 shares and bringing its total holdings to 36,397 shares valued at $6.156 million. Other institutional investors also adjusted their positions in CTAS, …

Praxis Precision Medicines (PRAX) Projected to Announce Earnings on Monday

Cinemark (CNK) Stock Price Ignores Record Cash Flow And Margin Surge

Price to book forward of MediciNova, Inc. – NASDAQ:MNOV

This article displays the "Price to book forward" for MediciNova, Inc. (NASDAQ: MNOV) on TradingView. It provides financial data for the company, accessible through various features on the platform. The main content shows the period, value, and change metrics for this financial indicator.

Scinai Immunotherapeutics Ltd (SCNI) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Scinai Immunotherapeutics Ltd (SCNI), noting its current valuation score of 7.40, ranking 176 out of 385 in its industry. It highlights the company's P/E ratio of -0.08, which is significantly below its recent high and above its …

Cingulate Inc. Revenue Breakdown – NASDAQ:CING

This article provides a financial overview of Cingulate Inc. (NASDAQ: CING), focusing on its revenue breakdown. It points to sections like "Fundamentals and stats," "Overview," "Statements," "Statistics," "Dividends," "Earnings," and "Segments" for detailed financial information. The content itself is very brief and seems to …

nCino, Inc. - Common Stock (Nasdaq:NCNO) Stock Quote

This article provides a stock quote for nCino, Inc. (NCNO) on the Nasdaq exchange, showing its current price, daily range, and recent performance metrics. It also includes a compilation of recent news headlines and press releases related to nCino, covering topics like earnings, AI …

Cincinnati Financial Corp. stock outperforms competitors on strong trading day

Shares of Cincinnati Financial Corp. (CINF) rose 1.69% on Friday, outperforming the broader market which also saw gains with the S&P 500 up 0.70% and the Dow Jones Industrial Average up 0.53%. This increase broke a three-day losing streak for the company's stock.

Cintas Corp. stock underperforms Friday when compared to competitors

Cintas Corp. (CTAS) stock fell 1.04% on Friday, closing at $204.63, despite a positive trading session for the broader market. Both the S&P 500 Index and the Dow Jones Industrial Average saw gains. This marks the second consecutive day of losses for Cintas Corp. …